Cartalax
AED peptide · Ala-Glu-Asp · T-31 · Khavinson cartilage tripeptide
Last updated
At a glance
Overview
What Cartalax Actually Does#
Cartalax — the Ala-Glu-Asp tripeptide, often labeled AED or T-31 — is a Khavinson short peptide bioregulator aimed squarely at cartilage, tendon, and connective-tissue gene expression. Unlike receptor-agonist peptides, it works at the chromatin level: the sequence penetrates cell and nuclear membranes via POT and LAT transporters, then modulates transcription of genes governing proliferation, senescence, and extracellular-matrix turnover.
In aging fibroblast cultures, AED upregulates Ki-67 and CD98hc while suppressing caspase-3 and MMP-9 — a gene-expression signature that reads as less matrix degradation, more proliferative capacity, less apoptotic drift. In mesenchymal stem-cell aging models it shifts IGF1, FOXO1, NF-κB, TERT, and TNKS2 toward a younger phenotype. The community interpretation is straightforward: a transcriptional nudge toward anabolic ECM remodeling in cartilage and skin, which is why it has found a niche among lifters rehabbing chronic joint wear, physique-focused users running quarterly Khavinson rotations, and looksmaxxers layering it into dermal-quality stacks.
"The AED peptide increased Ki-67 and CD98hc expression while decreasing caspase-3 activity and MMP-9 synthesis in aging skin fibroblasts." — Linkova et al., Bull Exp Biol Med 2016
Cartalax is not a BPC-157 substitute and does not feel like one. It is slow, cumulative, and pulsed — 10–20 day cycles, repeated every 4–6 months — with benefits that emerge over weeks rather than days. The sections below cover documented dosage ranges, the standard BPC-157 / TB-500 stack, injection-route considerations, cycle structure, half-life and administration frequency, and the side-effect and contraindication profile to work within.
How Cartalax works
Cartalax (Ala-Glu-Asp, "AED") is one of the Khavinson ultrashort peptides — a class of 2–7 amino acid sequences that act as transcriptional bioregulators rather than classical receptor ligands. Where BPC-157 works at the tissue-signaling layer, AED operates one level upstream: it enters the nucleus and biases gene expression in chondrocytes, fibroblasts, and mesenchymal stem cells toward an anabolic, youthful ECM-remodeling phenotype.
Membrane and Nuclear Penetration via POT/LAT Transporters#
The tripeptide is small (MW 333.3) and polar, which is exactly the substrate profile for the proton-coupled oligopeptide transporters (PEPT1/PEPT2) and L-type amino acid transporters (LAT) expressed on most cell types. These carriers deliver AED across the plasma membrane and — critically — across the nuclear envelope, where it reaches chromatin directly. This is why the plasma half-life of minutes does not limit the biological effect: the peptide is already inside the nucleus doing transcriptional work long after serum levels fall off.
"Ultrashort peptides cross cell and nuclear membranes via POT (PEPT1/PEPT2) and LAT transporters, supporting rapid systemic distribution after administration." — Khavinson V. et al., International Journal of Molecular Sciences, 2022
Practical upshot: pulsed dosing (10–20 day blocks, quarterly) is mechanistically coherent. Chronic daily administration is unnecessary because the downstream gene-expression shift outlives each dose.
Direct Chromatin-Level Gene Regulation#
Inside the nucleus, short Khavinson peptides dock into the minor groove of specific promoter sequences and interact with histone proteins, altering which genes are accessible to transcription machinery. This is a genuinely unusual mechanism — most peptides act at surface receptors and trigger second-messenger cascades; AED behaves more like a site-directed transcription factor.
"Short peptides such as AED interact with DNA and histone proteins, thus participating directly in gene regulation at the chromatin level." — Khavinson VKh, Lin'kova NS, Tarnovskaya SI, Bulletin of Experimental Biology and Medicine, 2016
This explains the slow, multi-week onset physique-focused users report. The peptide is reprogramming fibroblast and chondrocyte transcription, not acutely suppressing inflammation.
Fibroblast and Chondrocyte Proliferation with MMP-9 Suppression#
The most concrete phenotypic data on AED come from aging skin fibroblast cultures: Ki-67 (proliferation) and CD98hc (regeneration / amino-acid transport glycoprotein) are upregulated, while caspase-3 (apoptosis) and MMP-9 (matrix-degrading metalloprotease) are suppressed.
"The AED peptide increased Ki-67 and CD98hc expression while decreasing caspase-3 activity and MMP-9 synthesis in aging skin fibroblasts." — Linkova NS et al., Bulletin of Experimental Biology and Medicine, 2016
A follow-up comparison against the KE dipeptide found AED produced significantly greater proliferation-marker upregulation in the same fibroblast aging model — AED is the stronger tissue-anabolic signal of the two.
"AED demonstrated a significant upregulation of cell proliferation markers in aging fibroblasts compared to the KE peptide." — Fridman NV et al., Bulletin of Experimental Biology and Medicine, 2020
Practical upshot — cartalax for tendon repair and cartilage quality: fewer fibroblasts dying, more dividing, and less MMP-9 chewing up the collagen scaffold is exactly the cellular environment wanted for slow-turnover connective tissue. This is why the compound shows up in cartalax stacks with BPC-157 and TB-500 — the three mechanisms barely overlap.
Senescence Axis and Stem-Cell Longevity Signaling#
In replicative and stationary aging models of human mesenchymal stem cells, AED shifts a cluster of well-characterized longevity genes:
| Target | Direction | Functional role |
|---|---|---|
| IGF1 | modulated | anabolic / growth signaling |
| FOXO1 | modulated | stress resistance, proteostasis |
| NF-κB | modulated | inflammatory tone |
| TERT | modulated | telomerase catalytic subunit |
| TNKS2 | modulated | telomere maintenance, Wnt regulation |
"AED modulated the expression of IGF1, FOXO1, NF-κB, TERT, and TNKS2 in both replicative and stationary aging models of human mesenchymal stem cells." — Ashapkin V, Khavinson V et al., Molecular Biology Reports, 2020
Parallel work in renal-epithelial and fibroblast cultures shows suppression of the p16 / p21 / p53 senescence axis alongside elevation of SIRT6 — a sirtuin whose depletion alone is sufficient to drive chondrocyte senescence and MMP-1/MMP-13 upregulation. In other words, the same program AED moves is the program that, when broken, produces osteoarthritic cartilage.
Practical upshot: the cartilage/joint use case and the broader "longevity bioregulator" framing are the same mechanism viewed at different tissue scales. A physique-focused user running pulsed cartalax cycles for heavy-training joint wear is, on the cellular level, also executing a fibroblast-rejuvenation and senescence-reduction protocol — which is why the same peptide is rotated into skin-quality and connective-tissue-aesthetic stacks.
Why the Mechanism Is Slow-Acting (and Why That's Fine)#
Because the active site is the nucleus and the output is altered transcription, the clinical signal from a cartalax protocol emerges over weeks, not days — new mRNA, new protein, new ECM deposition. Users expecting BPC-157-style acute relief are disappointed; users who structure a 20-day pulsed cycle around a rehab block and re-assess at 6–8 weeks tend to report the characteristic reductions in joint stiffness and improvements in range of motion that the fibroblast/chondrocyte data would predict.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 2–3 mg | Once daily | Documented entry-level range |
| Mid | 3–4 mg | Once daily | Most commonly studied range |
| High | 4–5 mg | Once daily | Pulsed cycles of 10–20 days, repeated every 4–6 months. Continuous year-round administration is not supported by the literature. Injection site is typically subcutaneous abdomen; some protocols favor periarticular subq near the target joint. |
Cycle length & outcomes
Documented cycle
2–4 weeks
Plateau after
4 wks
Cycle Length & Protocol Design#
Cartalax follows the Khavinson pulsed-cycling tradition: short blocks of daily administration followed by extended washout, rather than continuous year-round use. The rationale is mechanistic — AED is a transcriptional modulator that shifts gene-expression patterns in fibroblasts and chondrocytes, and those shifts persist across cell generations after plasma peptide has cleared. Continuous dosing adds no documented benefit and is not how the bioregulator literature has ever deployed this class.
Cartalax Dosage by Goal#
| Goal | Cycle Length | Daily Dose | Repeat Interval |
|---|---|---|---|
| Maintenance / aging joint support | 10–15 days | 2 mg SC | Twice yearly |
| Skin fibroblast / ECM quality block | 20 days | 2–3 mg SC | Every 4–6 months |
| Tendon repair on heavy-training blocks | 20 days | 3–4 mg SC | Every 4–6 months |
| Chronic joint wear / advanced cartilage focus | 20–30 days | 4–5 mg SC | Every 4–6 months |
| Post-injury cartilage insult (front-loaded) | 10 days at 5 mg, then 10 days at 3 mg | — | Single block, reassess at 3 months |
A standard 20 mg vial reconstituted with 2–3 mL bacteriostatic water yields ~6.67–10 mg/mL, so a 3 mg dose is roughly 30–45 units on a U100 insulin syringe. Subcutaneous abdomen is the default site; periarticular subq near the target joint is common for knee and shoulder protocols, though no head-to-head data favor local over systemic delivery.
Loading, Tapering, and Frequency#
No loading phase is required or supported by the literature — the gene-expression response observed in fibroblast and MSC cultures develops within 24–72 hours of exposure and sustains through the block. The front-loaded post-injury protocol above (5 mg → 3 mg) is a community pattern, not a clinical standard.
Tapering is unnecessary. Cartalax is non-hormonal, does not touch the HPG axis, and produces no withdrawal phenomenon on discontinuation. The cycle simply ends.
Once-daily dosing is the norm. Some intermediate protocols split 4 mg into 2 mg AM / 2 mg PM to smooth plasma exposure, but given the short plasma half-life and the fact that effect lives downstream at the chromatin level, splitting is cosmetic rather than mechanistic.
Onset Timing#
Cartalax is a slow-feedback peptide. Users accustomed to BPC-157's rapid symptomatic relief consistently underrate Cartalax in the first week because nothing feels different. Expected timeline:
- Week 1: no perceptible change. Gene-expression shifts are occurring in target tissue but have not translated to symptomatic output.
- Weeks 2–3: stiffness reduction, subjective "looseness" in chronically affected joints.
- Week 4: improved range of motion, reduced flare frequency on heavy sessions.
- Weeks 6–8 post-cycle-start: peak subjective benefit. The gene-expression shift persists well past the last injection.
This latency is consistent with the mechanism:
The AED peptide increased Ki-67 and CD98hc expression while decreasing caspase-3 activity and MMP-9 synthesis in aging skin fibroblasts. — Linkova et al., Bull Exp Biol Med (2016)
AED modulated the expression of IGF1, FOXO1, NF-κB, TERT, and TNKS2 in both replicative and stationary aging models of human mesenchymal stem cells. — Ashapkin et al., Mol Biol Rep (2020)
Shifting transcription factors and matrix-remodeling enzymes takes days to manifest as tissue-level change; it takes weeks to manifest as symptom-level change.
Bloodwork Cadence#
Cartalax itself does not require compound-specific bloodwork. It is non-hormonal, does not perturb lipids, hepatic enzymes, hematocrit, or IGF-1, and carries no known interaction with AAS, SARM, or GH-axis panels.
For physique-focused users running Cartalax inside a larger PED program, the standard quarterly panel already in place (CBC, CMP, lipid panel, IGF-1, estradiol, total/free testosterone, SHBG) is sufficient. There is no Cartalax-attributable marker to chase.
The one flag worth naming: active or historical malignancy under surveillance is a hard contraindication. AED upregulates proliferation markers (Ki-67, CD98hc) and downregulates the p53/p16/p21 senescence axis — desirable in aging cartilage, undesirable near a tumor. This class should be avoided until oncology-safety data catches up.
Pulsed Rotation Strategy#
Experienced users running Khavinson peptides longitudinally tend to rotate compounds across the calendar rather than stacking all of them continuously. A representative quarterly schedule:
| Quarter | Primary Block | Focus |
|---|---|---|
| Q1 | Cartalax 3 mg × 20 days | Joints / cartilage / ECM |
| Q2 | AEDG (Epitalon) 5–10 mg × 10–20 days | Pineal / telomere axis |
| Q3 | Cartalax 3 mg × 20 days (repeat) | Joints / cartilage |
| Q4 | KED (Vesugen) or Pinealon | Vascular or CNS |
This preserves the pulsed-dosing logic that underlies the entire short-peptide literature and avoids the diminishing-returns trap of running a single bioregulator continuously. Two Cartalax blocks per year, spaced 4–6 months apart, is the sweet spot for the joint/tendon use case — and is what the community consistently returns to after experimenting with longer schedules.
Risks & mistakes
Common (most users)#
Cartalax is one of the cleanest compounds in the Khavinson short-peptide class. Across the published fibroblast, mesenchymal stem cell, and gene-expression work, no dose-limiting toxicity has been reported in the tested concentration ranges. Community reporting mirrors that signal — the tripeptide is small, non-immunogenic at research doses, and cleared from plasma in minutes.
- Injection-site erythema or mild soreness — typically resolves within a few hours. Rotating SC sites across the abdomen (or periarticular sites when local delivery is the goal) is sufficient. Ensuring full reconstitution before draw (gentle swirl, no shaking) and allowing the solution to reach room temperature reduces sting.
- Transient fatigue or "flat" feeling in the first 3–5 days of a cycle — inconsistent, often attributed to placebo/nocebo. No dose adjustment required; typically resolves on its own as the cycle progresses.
- Mild GI upset with oral cytamin-style preparations — rare with the injectable form. Splitting oral doses with food generally handles it.
- Slow perceived onset — not a side effect per se, but worth flagging: symptomatic improvement typically emerges over weeks, not days. Users expecting BPC-157-speed feedback will under-dose or abandon the cycle prematurely. The mechanism is transcriptional, and gene-expression shifts take cell-cycle time to translate into tissue-level changes.
Uncommon (dose-dependent or individual)#
- Diminishing returns above ~5 mg/day — the dose-response curve in the Khavinson-peptide literature is flat-to-inverted above a narrow window. Pushing to 8–10 mg/day chasing effect is not supported by the data and introduces cost without benefit. Back off to 3–4 mg if perceived response plateaus.
- Injection-site nodules with poor sterile technique — reconstituted peptide stored beyond 30 days, contaminated vial tops, or reused syringes are the usual culprits. Alcohol-swabbed tops, single-use insulin syringes, and refrigerated storage resolve it.
- Headache or mild pressure sensation — occasionally reported when Cartalax is stacked with other bioregulators (Pinealon, Epitalon) at the top of their respective dose ranges. Dropping one compound to its low end clarifies attribution.
- No significant bloodwork perturbation expected — lifters already tracking lipids, liver enzymes, hematocrit, and IGF-1 quarterly have not reported disruption attributable to AED. Continue standard on-cycle monitoring; Cartalax does not change the panel.
Rare but serious#
No serious adverse events have been reported in the published AED literature or in community practice at standard research doses. The theoretical concerns worth naming:
- Unmasking or acceleration of occult proliferative pathology — AED upregulates Ki-67 and CD98hc and downregulates caspase-3 and MMP-9 in fibroblasts:
"The AED peptide increased Ki-67 and CD98hc expression while decreasing caspase-3 activity and MMP-9 synthesis in aging skin fibroblasts." — Linkova et al., Bull Exp Biol Med 2016
Combined with its documented effect on the senescence and anti-apoptotic gene axis in stem cell cultures:
"AED modulated the expression of IGF1, FOXO1, NF-κB, TERT, and TNKS2 in both replicative and stationary aging models of human mesenchymal stem cells." — Ashapkin et al., Mol Biol Rep 2020
...this constitutes a plausible (not demonstrated) concern in subjects harboring undiagnosed malignancy. Warning signs warranting cycle termination and workup: unexplained weight loss, persistent lymphadenopathy, new-onset bleeding, or a rapidly changing skin lesion.
- Hypersensitivity reaction to a low-purity or mis-sequenced vial — the peptide is trivial to synthesize, which is both a QC advantage and a QC liability depending on the vendor. HPLC/MS certificates of analysis are the mitigation. Systemic urticaria, facial swelling, or respiratory symptoms after injection means stop, investigate the vial.
Hard contraindications#
These lines do not move:
- Active malignancy. AED biases gene expression toward proliferation (↑Ki-67, ↑CD98hc) and suppresses the p53/p16/p21 senescence axis. That profile is desirable in aging cartilage and undesirable in a tumor. Do not run Cartalax concurrent with active oncologic disease.
- Personal history of malignancy under active surveillance. Until AED has dedicated oncology-safety data, subjects in active surveillance windows fall on the wrong side of the risk/benefit line.
- Pregnancy and lactation. No reproductive toxicology data exist for AED. Excluded.
- Known peptide hypersensitivity. Prior anaphylactoid reaction to any injectable peptide excludes further research use without allergy workup.
- Unverified raw material. Cartalax from a vendor without HPLC/MS COA is not a Cartalax cycle — it is an unknown. Hard rule: no COA, no injection.
Gender and PCT considerations#
Cartalax is a non-hormonal transcriptional modulator. It does not bind androgen, estrogen, or progesterone receptors, does not affect the HPG axis, and does not influence LH/FSH/testosterone/estradiol. There is no virilization risk for female subjects, no HPTA suppression in male subjects, and no PCT is required after a cycle.
Dosing is weight-independent and applies equivalently across the subject pool — the 2–5 mg/day range is the same for a 60 kg female research subject as for a 110 kg male one. The only gender-specific cautions are the pregnancy and lactation exclusions stated above.
FAQ — Cartalax
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy Cartalax, 20mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Cartalax
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- CartalaxBuy Cartalax
Research & citations
5 studies cited on this page.
Conclusion
Cartalax is a well-established short peptide for connective-tissue and cartilage-focused regeneration — distinguished by its transcriptional effects on chondrocytes and fibroblasts, not just local inflammation.
Key takeaways:
- Typical dose: 2–5mg subq once daily, pulsed for 10–20 days; higher-end dosing (4–5mg) favored in joint-intensive protocols
- Preferred route: subcutaneous; periarticular subq is common when targeting specific joints, but abdominal subq is supported in the literature
- Pulsed cycles: 2–4 weeks on, then 4–6 months off; continuous year-round administration is not supported
- Stacking: Cartalax synergizes with BPC-157 (250–500µg SC daily) and/or TB-500 (2mg twice weekly) for a comprehensive tendon/ECM recovery stack
- Mechanism: drives ECM remodeling via direct gene regulation — upregulates cell proliferation markers and downregulates matrix degradation (reference: Linkova et al. 2016)
- Minimal side effect profile when administered with proper sterile technique; strong caution for active malignancy given the proliferative mechanism
For research into joint repair, chronic tendinopathies, or supporting connective-tissue recovery on demanding PED cycles, Cartalax is a confident pick centering mechanistic synergy and durable, transcription-level effects.